Compare Gold Fields Limited (GFI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs ResMed Inc. — how do they compare? Gold Fields Limited trades at $36.85 (market cap $31.87B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: Gold Fields Limited and ResMed Inc. are close in size by market cap, and Gold Fields Limited pays the higher dividend (6%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and ResMed Inc. for 51 Days on average.
| GFI | RMD | |
|---|---|---|
Market Cap | $31.87B | $31.89B |
Volume | 4,169,651 | 618,314 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $277.88 |
52-Week Low | $31.25 | $182.82 |
Typical Hold Time | 49 Days | 51 Days |
Enterprise Value | $32.47B | $31.24B |
Dividend Yield | 6% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.82, up 5.05% today, amid mixed technical signals with a bearish overall trend. Fundamentally, the company shows strong profitability with 38.66% net margins and robust cash flow generation of $3.77B from operations in 2025. Recent news highlights the rejected $27B Northern Star takeover bid and strong operational performance from Salares Norte, driving investor attention to the company's capital allocation strategy.
The investment outlook balances strong fundamentals against acquisition risks and technical weakness. With 44% analyst buy ratings and a $52.75 price target suggesting 43% upside, GFI presents value opportunity, though recent earnings misses and bearish technicals warrant caution. Key risks include execution on growth projects and gold price volatility.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
